Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $1.0 million.

  • Century Therapeutics' Other Accumulated Expenses rose 113214.29% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 113214.29%. This contributed to the annual value of $75000.0 for FY2024, which is 16785.71% up from last year.
  • According to the latest figures from Q3 2025, Century Therapeutics' Other Accumulated Expenses is $1.0 million, which was up 113214.29% from $49000.0 recorded in Q2 2025.
  • Century Therapeutics' 5-year Other Accumulated Expenses high stood at $1.0 million for Q3 2025, and its period low was $11000.0 during Q2 2023.
  • Its 4-year average for Other Accumulated Expenses is $164000.0, with a median of $75000.0 in 2024.
  • In the last 5 years, Century Therapeutics' Other Accumulated Expenses plummeted by 8813.56% in 2023 and then surged by 113214.29% in 2025.
  • Over the past 4 years, Century Therapeutics' Other Accumulated Expenses (Quarter) stood at $236000.0 in 2022, then plummeted by 88.14% to $28000.0 in 2023, then skyrocketed by 167.86% to $75000.0 in 2024, then soared by 1280.0% to $1.0 million in 2025.
  • Its Other Accumulated Expenses was $1.0 million in Q3 2025, compared to $49000.0 in Q2 2025 and $111000.0 in Q1 2025.